NCT00687401View on ClinicalTrials.gov

A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)

PHASE3CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Psoriasis
Interventions
BIOLOGICAL

Infliximab

Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00687401 - A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612) | Biotech Hunter | Biotech Hunter